LBLucia Bisceglia

Lucia Bisceglia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucia Bisceglia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Models for Disease Progression and Outcomes in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

    by Deborah Testa, Pietro Magnoni, Caterina Fanizza, Martino Bussa, Adele Zanfino, Dariush Khaleghi Hashemian, Paola Rebora, Lucia Bisceglia, Antonio Giampiero Russo

    Background/Objectives: Prevalence and burden of chronic obstructive pulmonary disease (COPD) are projected to increase in the coming decades. Although prognostic models for disease progression and exacerbation risk have proliferated, especially with the advent of machine learning (ML), their methodological rigor, generalizability, and predictive performance remain inconsistent. This study aimed to systematically review prognostic models for disease progression in adults with COPD, including traditional regression-based methods and ML techniques, evaluating model performance, sources of heterogeneity and methodological issues. Methods: PubMed and Embase were searched for all studies that developed and/or validated prognostic models for mortality (overall and cause-specific), exacerbations, or hospitalizations in adults with COPD over a time window of 1–5 years. Methodological quality was appraised using PROBAST. Model performance was summarized descriptively, and discrimination (c-statistic) was meta-analyzed for externally validated models with sufficient homogeneity. Results: Eighty-seven studies presenting 193 prognostic models across 96 unique cohorts were included. Only 7% of models were based on ML. Thirty-eight percent of records were validations of multidimensional indices. All-cause mortality (n = 85), severe exacerbations (n = 38) and moderate/severe exacerbations (n = 16) were the most frequently studied outcomes. Meta-analysis of exacerbation models was hampered by insufficient homogeneity (median c 0.74). As for mortality, BODE outperformed other indices (pooled c 0.75). Over 40% of studies were flawed by a high risk of bias. Conclusions: Despite a comprehensive literature search and thorough data extraction, we were able to provide a meaningful quantitative synthesis only for externally validated mortality models, as pooling results for other individual outcomes was precluded by substantial heterogeneity. Our findings highlight the predominance of regression approaches, the limited use of ML, the presence of persistent methodological limitations and the need for more robust, validated models capable of handling complex, multimodal patient data.


  • Open Access

    Estimating the Proportion of Asymptomatic COVID‐19 Cases in an Italian Region with Intermediate Incidence during the First Pandemic Wave: An Observational Retrospective Study

    by Domenico Martinelli, Francesca Fortunato, Sara Mazzilli, Lucia Bisceglia, Pier Luigi Lopalco, Rosa Prato

    Early in the COVID‐19 pandemic, asymptomatic transmission represented an important challenge for controlling the spread of SARS‐CoV‐2 through the traditional public health strategies. Further understanding of the contribution of asymptomatic infections to SARS‐CoV‐2 transmission has been of crucial importance for pandemic control. We conducted a retrospective epidemiological study to characterize asymptomatic COVID‐19 cases occurred in the Apulia region, Italy, during the first epidemic wave of COVID‐19 outbreak (February 29‐July 7, 2020). We analyzed data collected in a regional platform developed to manage surveillance activities, namely, investigation and follow‐up of cases and contacts, contact tracing, and laboratory and clinical data collection. We included all asymptomatic cases that were laboratory‐confirmed during the appropriate follow‐up, defined as persons infected with SARS‐CoV‐2 who did not develop symptoms/clinical signs of the disease. Between February 29 and July 7, 2020, a total of 4,536 cases were diagnosed with COVID‐19 among 193,757 tests performed. The group of persons with asymptomatic SARS‐CoV‐2 infection consisted of 903 cases; the asymptomatic proportion was 19.9% (95% CI: 18.8‐21.1%); this decreased with increasing age (OR: 0.89, 95% CI: 0.83‐0.96; p = 0.001), in individuals with underlying comorbidities (OR: 0.55, 95% CI: 0.41‐0.73; p < 0.001), and in males (OR: 0.69, 95% CI: 0.54‐0.87; p = 0.002). The median asymptomatic SARS‐CoV‐2 RNA positive period was 19 days (IQR: 14‐31) and the cumulative proportion of persons with resolution of infection 14 days after the first positive PCR test was 74%. As the public health community is debating the question of whether asymptomatic and late spreaders could sustain virus transmission in the communities, such cases present unique opportunities to gain insight into SARS‐CoV‐2 adaptation to human host. This has important implications for future COVID‐19 surveillance and prevention.